METASTATIC URETHRAL UROTHELIAL CARCINOMA
Clinical trials for METASTATIC URETHRAL UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC URETHRAL UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC URETHRAL UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy trial offers hope for Tough-to-Treat bladder cancer
Disease control OngoingThis study is testing whether adding a chemotherapy drug (eribulin) to an immunotherapy drug (atezolizumab) works better than the immunotherapy drug alone for people with advanced bladder cancer that has spread or come back. It is for patients who cannot take a standard chemother…
Matched conditions: METASTATIC URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug duo aims to attack tough bladder cancer
Disease control OngoingThis early-phase trial is testing the safety and best dose of a two-drug combination for people with advanced bladder cancer that has spread and has specific genetic changes (FGFR2/3). The study is for patients whose cancer has continued to grow despite trying standard chemothera…
Matched conditions: METASTATIC URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Personalized cancer fight: matching drugs to your Tumor's genetic fingerprint
Disease control OngoingThis study is testing whether specific genetic markers in a patient's tumor can predict if they will respond well to immunotherapy drugs. It is for people with advanced bladder cancer that has spread and has stopped responding to standard chemotherapy. Participants receive two im…
Matched conditions: METASTATIC URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Heart drug joins fight against bladder cancer
Disease control OngoingThis study is testing if adding a common, low-cost blood pressure medication called propranolol to standard immunotherapy helps people with advanced bladder cancer. Six participants will receive either immunotherapy alone or immunotherapy plus propranolol. The main goal is to see…
Matched conditions: METASTATIC URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Cancer trial asks: can patients stop treatment sooner and stay well?
Disease control OngoingThis study is for people with advanced bladder cancer who have already had about a year of immunotherapy. It compares two approaches: continuing the immunotherapy treatment versus stopping it. The main goal is to see if stopping treatment leads to similar survival rates while pot…
Matched conditions: METASTATIC URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo tested for aggressive bladder and prostate cancers
Disease control OngoingThis early-stage trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy works better for treating advanced small cell or neuroendocrine cancers of the bladder, urethra, or prostate. The study will enroll about 15 participants with cancer tha…
Matched conditions: METASTATIC URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug combo aims to keep advanced bladder cancer at bay
Disease control OngoingThis large, late-stage trial is testing if adding a pill called cabozantinib to an immunotherapy drug (avelumab) is better than the immunotherapy alone for keeping advanced bladder cancer from growing or returning. It is for patients whose cancer did not worsen after their first …
Matched conditions: METASTATIC URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New cancer combo aims to supercharge immune system while taming side effects
Disease control OngoingThis study is testing a combination of three immunotherapy drugs—tocilizumab, ipilimumab, and nivolumab—in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. The main goal is to see if adding tocilizumab can help manage the serious side effects someti…
Matched conditions: METASTATIC URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC